Vitamin B₁₂ and risk of diabetes: new insight from cross-sectional and longitudinal analyses of the China Stroke Primary Prevention Trial (CSPPT)

Lishun Liu,¹ Xiao Huang,² Binyan Wang,^{3,4,5} Yun Song,¹ Tengfei Lin,¹ Ziyi Zhou,¹ Zhuo Wang,¹ Yaping Wei,¹ Huiyuan Guo,¹ Ping Chen,⁶ Yan Yang,^{7,8} Wenhua Ling,^{8,9} Youbao Li,³ Xianhui Qin,^{3,4} Genfu Tang,⁴ Chengzhang Liu,⁵ Jianping Li,¹⁰ Yan Zhang,¹⁰ Pierre A Zalloua,¹¹ Xiaobin Wang,¹² Yong Huo,¹⁰ Hao Zhang ¹, Xiping Xu^{1,3}

To cite: Liu L, Huang X, Wang B, *et al.* Vitamin B₁₂ and risk of diabetes: new insight from cross-sectional and longitudinal analyses of the China Stroke Primary Prevention Trial (CSPPT). *BMJ Open Diab Res Care* 2020;**8**:e001423. doi:10.1136/bmjdr-2020-001423

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bmjdr-2020-001423>).

Received 30 March 2020
Revised 3 June 2020
Accepted 8 June 2020

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Hao Zhang;
zhcau2019@126.com and Dr Xiping Xu;
xipingxu126@126.com

ABSTRACT

Introduction Previous studies in mostly Western populations have yielded conflicting findings on the association of vitamin B₁₂ with diabetes risk, in part due to differences in study design and population characteristics. This study sought to examine the vitamin B₁₂-diabetes association in Chinese adults with hypertension by both cross-sectional and longitudinal analyses.

Research design and methods This report included a total of 16 699 participants from the China Stroke Primary Prevention Trial, with pertinent baseline and follow-up data. Diabetes mellitus was defined as either physician-diagnosed diabetes, use of glucose-lowering drugs, or fasting blood glucose (FBG) ≥ 7.0 mmol/L. New-onset diabetes was defined as any new case of onset diabetes during the follow-up period or FBG ≥ 7.0 mmol/L at the exit visit.

Results At baseline, there were 1872 (11.2%) patients with diabetes; less than 1.5% had clinical vitamin B₁₂ deficiency (<148.0 pmol/L). Over a median follow-up period of 4.5 years, there were 1589 (10.7%) cases of new-onset diabetes. Cross-sectional analyses showed a positive association between baseline vitamin B₁₂ levels and FBG levels ($\beta=0.18$, 95% CI 0.15 to 0.21) and diabetes (OR=1.16, 95% CI 1.10 to 1.21). However, longitudinal analyses showed no association between baseline vitamin B₁₂ and new-onset diabetes or changes in FBG levels. Among a subset of the sample (n=4366) with both baseline and exit vitamin B₁₂ measurements, we found a positive association between an increase in vitamin B₁₂ and an increase in FBG.

Conclusions In this large Chinese population of patients with hypertension mostly sufficient with vitamin B₁₂, parallel cross-sectional and longitudinal analyses provided new insight into the conflicting findings of previous studies, and these results underscore the need for future studies to consider both baseline vitamin B₁₂ and its longitudinal trajectory in order to better elucidate the role of vitamin B₁₂ in the development of diabetes. Such findings would have important clinical and public health implications.

INTRODUCTION

Diabetes mellitus (DM) is a chronic metabolic disorder that has reached epidemic

Significance of this study

What is already known about this subject?

- Conflicting findings were derived from previous studies on B₁₂ and diabetes using either cross-sectional or longitudinal design. Some cross-sectional studies found that B₁₂ was positively associated with diabetes, while others reported the opposite results. Several longitudinal studies showed no significant relationship between B₁₂ and DM).
- To date, the relationship between B₁₂ and DM has remained elusive.

What are the new findings?

- This is the first and largest study of a Chinese population of patients with hypertension (n=16 699) to delineate cross-sectional and longitudinal associations between plasma vitamin B₁₂ and diabetes risk.
- The cross-sectional analyses showed a positive association between baseline vitamin B₁₂ levels and diabetes; however, longitudinal analyses revealed no association. Among a subset of sample (n=4366) with both baseline and exit B₁₂ levels, we found a positive association between an increase in B₁₂ and an increase in fasting blood glucose.

How might these results change the focus of research or clinical practice?

- Findings from our cross-sectional and longitudinal analyses underscore the need for future studies to consider both baseline vitamin B₁₂ and its longitudinal trajectory in order to better elucidate the role of vitamin B₁₂ in the development of diabetes.
- Such findings, if further confirmed, have important clinical and public health implications.

levels around the world.¹ In China, there has been a sharp increase in diabetes prevalence in the past few decades, and currently 11.4 million people have diabetes.² From both clinical and public health perspectives, there is a critical need to develop

cost-effective strategies to prevent diabetes. Vitamin B₁₂ is a coenzyme in the one-carbon metabolic pathway involved in the synthesis of methionine and pyrimidine and purine bases. Deficiencies in vitamin B₁₂ and associated DNA damage and subsequent faulty repair are known to contribute to the development of vascular diseases, cancer, and some birth defects, and can lead to hyperhomocysteinemia. Often related to folic acid deficiency, vitamin B₁₂ has been identified as a risk factor for both hypertension and atherosclerosis.³

To date, most studies on vitamin B₁₂ and DM have been centered on vitamin B₁₂ deficiency among existing patients with diabetes. The association between metformin use and low vitamin B₁₂ levels has been supported by various levels of evidence.⁴ Because ileal vitamin B₁₂ absorption is a calcium-dependent process, and metformin is known to have an effect on calcium-dependent membrane action, patients with type 2 diabetes usually developed a marked reduction in serum vitamin B₁₂ while being treated with metformin.⁵ However, the risks and benefits of vitamin B₁₂ on future risk of DM are not clear due to inconsistent results of previous studies. A cross-sectional study in a South Indian population showed that higher vitamin B₁₂ levels decreased the risk of DM.⁶ Another longitudinal randomized control trial study showed no difference in the incidence of type 2 diabetes mellitus between the vitamin B₁₂-supplemented group as compared with the non-supplemented control group.⁷ The current study addresses an important yet controversial topic of whether vitamin B₁₂ is associated with DM.

This current study was motivated by the findings of the US National Health and Nutrition Examination Survey (NHANES)⁸ which showed that vitamin B₁₂ levels in patients with DM without metformin were significantly higher than those in the general population. However, the NHANES is a cross-sectional study, and in order to address whether vitamin B₁₂ levels that are higher than the optimal range are a risk factor for developing DM, a prospective cohort study would be required to assess the temporal and dose–response relationship.

In this report, we analyzed a total of 16 699 participants with hypertension from the China Stroke Primary Prevention Trial (CSPPT), with pertinent baseline data and a mean follow-up of 4.5 years. Our primary objective is to perform both cross-sectional and longitudinal analyses with the aim of determining whether the findings of the NHANES could be replicated in a Chinese population, and furthermore whether there is a prospective and dose–response association between baseline vitamin B₁₂ levels and risk of new-onset DM. Among a subset of the sample (n=4366) with both baseline and exit vitamin B₁₂ measurements, we further analyzed the relationship between the change in vitamin B₁₂ levels and the change in fasting blood glucose (FBG) levels from baseline to the exit visit as the secondary objective.

RESEARCH DESIGN AND METHODS

Participants and trial design

All participants provided written, informed consent. A total of 20 702 eligible participants, stratified by the methylenetetrahydrofolate reductase (*MTHFR*) C677T genotypes (CC, CT, or TT), were randomly assigned, in a 1:1 ratio, to one of two treatment groups: a daily oral dose of one tablet containing 10 mg enalapril and 0.8 mg folic acid (the enalapril-folic acid group), or a daily oral dose of one tablet containing 10 mg enalapril only (the enalapril group). Participants were engaged in follow-up visits every 3 months.

A detailed description and the primary results of the CSPPT have been reported elsewhere.^{9–11} Briefly, the CSPPT was a multicommunity, randomized, double-blind, controlled trial conducted between May 19, 2008 and August 24, 2013 in 32 communities in China. Eligible participants were men and women aged 45–75 years with hypertension, defined as seated, resting systolic blood pressure (SBP) ≥140 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg at both the screening and recruitment visit, or who were taking antihypertensive medication. The major exclusion criteria included history of physician-diagnosed stroke, myocardial infarction (MI), heart failure, postcoronary revascularization, or congenital heart disease. According to the CSPPT study protocol people who had long-term B-group vitamin supplementation were excluded, and other B-group vitamins should not be supplemented during the study period.

This report included 16 699 men and women with hypertension from the CSPPT with baseline vitamin B₁₂ data and pertinent baseline and follow-up data on diabetes status and covariables. As illustrated in the flow chart (online supplementary figure S1), the final analyses excluded participants with missing values for baseline vitamin B₁₂, baseline FBG, exit FBG and with any missing data on the follow-up questionnaire. We also randomly selected a subset of the population (n=4366) to detect changes in vitamin B₁₂ at the exit visit (online supplementary table S1).

Outcomes

Patients were classified as diabetic if they self-reported a physician diagnosis, or were using glucose-lowering medication, or when their FBG ≥7.0 mmol/L at baseline.¹² New-onset diabetes was defined as a self-reported physician diagnosis, or use of glucose-lowering drugs during the follow-up period, or when FBG changed from <7.0 mmol/L at baseline to ≥7.0 mmol/L at the last study (exit) visit.

Covariables

Covariables included known or suspected factors associated with vitamin B₁₂ and/or DM based on existing literature, including our own studies in the CSPPT, specifically age, sex, *MTHFR* gene C677T polymorphisms, SBP and DBP at baseline, mean SBP and DBP during the treatment

period, body mass index (BMI), study center, serum concentrations of folate, total homocysteine (tHcy), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), smoking status, alcohol consumption status, self-reported meat consumption and medication use. Information on meat consumption was self-reported at baseline using a simple abbreviated semi-quantitative Food Frequency Questionnaire. Participants were asked to report how often, on average, they eat meat every week. Possible response categories included 'never', '1–2 times/week', '3–5 times/week' and 'every day'. Vitamin B₁₂ deficiency was defined as vitamin B₁₂ <148.0 pmol/L.¹³

Laboratory assays

For biochemical analyses, 20 mL blood samples were collected between 7:00 and 9:00 after an overnight fast (at least 8 hours). Serum samples were separated, aliquoted and subsequently stored at –80°C until analysis. Plasma vitamin B₁₂ at baseline and folate at baseline and the exit visit were measured using a chemiluminescent immunoassay at the commercial lab (New Industrial, Shenzhen, China). tHcy, fasting lipids and FBG at baseline and the exit visit were measured using automatic clinical analyzers (Beckman Coulter, California, USA) at the core lab of the National Clinical Research Center for Kidney Disease (Nanfang Hospital, Guangzhou, China).

Statistical analysis

Descriptive data are presented as mean (SD) or median values with IQR in parentheses or proportions, as appropriate, for population characteristics according to baseline vitamin B₁₂ quartiles. The significance of differences in population characteristics between groups was computed using two-sample t-tests, signed-rank tests, or χ^2 tests for continuous and categorical variables.

Logistic regression models were used to estimate the ORs and their 95% CIs of diabetes, given the exact onset of diabetes was not known and many new-onset DM cases were detected by fasting glucose levels at the exit visit. All analyses were conducted with adjustments for covariables. Finally, subgroup analyses were performed to evaluate possible effect modifications by the covariables on the association between vitamin B₁₂ and DM, including sex (male vs female), age (<60 vs ≥60 years), *MTHFR* C677T polymorphism (CC vs CT vs TT), SBP (<160.0 vs ≥160.0 mm Hg), DBP (<90 vs ≥90 mm Hg), mean SBP during the treatment period (<140.0 vs ≥140.0 mm Hg), mean DBP during the treatment period (<90 vs ≥90 mm Hg), BMI (<25 vs ≥25 kg/m²), study center (Anqing vs Lianyungang), folate (<8 vs ≥8 ng/mL), tHcy (<12.5 vs ≥12.5 μmol/L), TC (<5.5 vs ≥5.5 mmol/L), TG (<1.5 vs ≥1.5 mmol/L), HDL-C (<1.3 vs ≥1.3 mmol/L) and treatment group (enalapril vs enalapril-folic acid). A two-tailed *p*<0.05 was considered significant in all analyses. All statistical analyses were performed using R software,

V.3.6.0 (<http://www.R-project.org/>, accessed April 26, 2019).

RESULTS

Study participants and baseline characteristics

Study participants had an average age of 60.0 years (SD 7.4), 6713 were male (40.2%) and 9986 were female (59.8%) (online supplementary table S2). Participants had an average vitamin B₁₂ level of 295.9 pmol/L (SD 91.5), 257 (1.5%) participants had vitamin B₁₂ deficiency, while 10 468 (63.3%) participants did not consume meat. The mean FBG level was 5.8 mmol/L (SD 1.7) at baseline, and the exit mean FBG level was 6.3 mmol/L (SD 2.0). At baseline, 1872 (11.2%) participants had DM, and at the exit visit there were 1589 (10.7%) cases of new-onset DM. When stratified by baseline vitamin B₁₂ quartiles, FBG levels were the highest (6.0 mmol/L (SD 2.1)) in the fourth quartile (Q4). Table 1 shows that the average age and BMI of the participants in Q4 were lower than those of the other groups, but TC and TG levels were higher than the other quartiles.

Cross-sectional analysis on baseline vitamin B₁₂ and DM

From the cross-sectional analysis, vitamin B₁₂ was found to be positively associated with DM (OR=1.35, 95% CI 1.26 to 1.44, *p*<0.001) at baseline (table 2). After stratifying by vitamin B₁₂ quartiles, participants in Q4 were found to have the highest risk (OR=1.68, 95% CI 1.43 to 1.98, *p*<0.001). Also, there was a positive association between vitamin B₁₂ and FBG (β =0.14, 95% CI 0.11 to 0.17, *p*<0.001) (table 3). After stratifying by relevant covariables, we discovered interactions between sex, TC levels and vitamin B₁₂ with baseline DM and FBG (online supplementary figure S2, online supplementary figure S3). No interaction was found between vitamin B₁₂ and plasma folic acid or tHcy.

Longitudinal analyses on baseline vitamin B₁₂ and new-onset DM

Longitudinal analyses did not show an association between baseline vitamin B₁₂ and new-onset DM (OR=0.97, 95% CI 0.90 to 1.04, *p*=0.346) (table 2), change in FBG (β =–0.01, 95% CI –0.04 to 0.02, *p*=0.602), or exit FBG (β =–0.01, 95% CI –0.04 to 0.02, *p*=0.602) after making additional adjustments for baseline FBG (table 3). After stratifying by relevant covariables, no interaction was found between vitamin B₁₂ with new-onset DM, exit FBG or change in FBG (online supplementary figure S2, online supplementary figure S3).

Longitudinal analyses on change in vitamin B₁₂ levels and change in FBG levels

Among a subset of the sample (*n*=4366) with both baseline and exit vitamin B₁₂ measurements, we further analyzed the relationship between change in vitamin B₁₂ levels and change in FBG levels from the baseline to the exit visit. We found a dose–response relationship between

Table 1 Baseline and follow-up characteristics of the study participants by baseline B₁₂ quartiles

Variables	Total	Baseline vitamin B ₁₂ quartiles (pmol/L)				P value
		Q1 (<232.3)	Q2 (232.3–279.4)	Q3 (279.4–349.8)	Q4 (≥349.8)	
n	16699	4175	4173	4176	4175	
Age (years)	60.0 (7.4)	60.4 (7.4)	60.1 (7.5)	59.7 (7.4)	59.9 (7.3)	<0.001
Male	6713 (40.2%)	1833 (43.9%)	1632 (39.1%)	1661 (39.8%)	1587 (38.0%)	<0.001
BMI (kg/m ²)	25.0 (3.7)	24.9 (3.6)	25.2 (3.7)	25.2 (3.7)	24.8 (3.6)	<0.001
Total cholesterol (mmol/L)	5.5 (1.2)	5.3 (1.1)	5.5 (1.2)	5.6 (1.2)	5.7 (1.3)	<0.001
Triglycerides (mmol/L)	1.7 (1.2)	1.6 (0.9)	1.6 (0.9)	1.7 (1.0)	1.7 (1.8)	<0.001
HDL-C (mmol/L)	1.3 (0.4)	1.3 (0.3)	1.3 (0.4)	1.3 (0.4)	1.4 (0.4)	<0.001
ALT (U/L)	49.1 (5.8)	48.3 (5.6)	49.1 (5.8)	49.6 (5.8)	49.5 (5.8)	<0.001
AST (U/L)	26.1 (36.5)	24.8 (9)	24.6 (9.1)	25.9 (11.1)	29.2 (70.8)	<0.001
FBG (mmol/L)	5.8 (1.7)	5.6 (1.3)	5.8 (1.5)	5.9 (1.7)	6.0 (2.1)	<0.001
Exit FBG (mmol/L)	6.3 (2.0)	6.1 (1.7)	6.2 (2.0)	6.3 (2.1)	6.4 (2.2)	<0.001
Folate (ng/mL)	8.0 (5.6–10.4)	7.5 (5.2–9.9)	7.7 (5.4–10)	8.1 (5.7–10.4)	8.7 (6.1–11.1)	<0.001
B ₁₂ (pmol/L)	277.8 (231.7–345.7)	205.7 (184.7–219.8)	254.8 (243.8–266.6)	308.7 (292.6–327.5)	409.5 (375.6–460.2)	<0.001
Homocysteine (μmol/L)	12.5 (10.4–15.4)	13.8 (11.3–17.5)	12.7 (10.6–15.9)	12.1 (10.3–14.6)	11.6 (9.8–13.9)	<0.001
eGFR (mL/min per 1.73 m ²)	93.6 (13.0)	93.8 (12.5)	93.6 (13.0)	94.0 (12.7)	92.8 (13.6)	<0.001
SBP (mm Hg)	167.2 (20.4)	165.7 (20.1)	167.4 (20.4)	168.4 (20.8)	167.4 (20.3)	<0.001
DBP (mm Hg)	94.2 (11.9)	93.2 (12.0)	94.2 (11.8)	94.8 (11.8)	94.4 (11.9)	<0.001
Mean SBP during the treatment period (mm Hg)	139.0 (10.6)	139.1 (10.8)	139.0 (10.5)	138.9 (10.4)	138.8 (10.5)	0.641
Mean DBP during the treatment period (mm Hg)	82.8 (7.2)	82.6 (7.4)	82.8 (7.3)	83.0 (7.1)	82.7 (7.1)	0.058
MTHFR C677T						<0.001
CC	4529 (27.1%)	1047 (25.1%)	1060 (25.4%)	1163 (27.8%)	1259 (30.2%)	
CT	8185 (49.0%)	1962 (47.0%)	2015 (48.3%)	2121 (50.8%)	2087 (50.0%)	
TT	3985 (23.9%)	1166 (27.9%)	1098 (26.3%)	892 (21.4%)	829 (19.9%)	
Treatment group						0.814
Enalapril	8369 (50.1%)	2076 (49.7%)	2098 (50.3%)	2080 (49.8%)	2115 (50.7%)	
Enalapril-folic acid	8330 (49.9%)	2099 (50.3%)	2075 (49.7%)	2096 (50.2%)	2060 (49.3%)	
Center						<0.001
Anqing	3905 (23.4%)	869 (20.8%)	712 (17.1%)	946 (22.7%)	1378 (33.0%)	
Lianyungang	12794 (76.6%)	3306 (79.2%)	3461 (82.9%)	3230 (77.3%)	2797 (67.0%)	
Smoking status						<0.001
Never	11613 (69.6%)	2778 (66.6%)	2941 (70.5%)	2917 (69.9%)	2977 (71.3%)	

Continued

Table 1 Continued

Variables	Total	Baseline vitamin B ₁₂ quartiles (pmol/L)				P value
		Q1 (<232.3)	Q2 (232.3–279.4)	Q3 (279.4–349.8)	Q4 (≥349.8)	
Former	1259 (7.5%)	322 (7.7%)	271 (6.5%)	313 (7.5%)	353 (8.5%)	
Current	3820 (22.9%)	1072 (25.7%)	960 (23.0%)	945 (22.6%)	843 (20.2%)	
Alcohol drinking						0.334
Never	11 596 (69.5%)	2858 (68.5%)	2959 (70.9%)	2878 (68.9%)	2901 (69.5%)	
Former	1145 (6.9%)	290 (7.0%)	279 (6.7%)	292 (7.0%)	284 (6.8%)	
Current	3947 (23.7%)	1022 (24.5%)	933 (22.4%)	1005 (24.1%)	987 (23.7%)	
Meat consumption						<0.001
Never	10 468 (63.3%)	2788 (68.0%)	2671 (64.6%)	2562 (61.7%)	2447 (59.1%)	
1–2 times per week	4642 (28.1%)	1069 (26.1%)	1131 (27.4%)	1186 (28.6%)	1256 (30.3%)	
3–5 times per week	978 (5.9%)	173 (4.2%)	227 (5.5%)	292 (7.0%)	286 (6.9%)	
Every day	442 (2.7%)	71 (1.7%)	106 (2.6%)	112 (2.7%)	153 (3.7%)	
Medication use						
Antidiabetic drugs	260 (1.6%)	33 (0.8%)	46 (1.1%)	73 (1.7%)	108 (2.6%)	<0.001
Lipid-lowering drugs	141 (0.8%)	32 (0.8%)	36 (0.9%)	32 (0.8%)	41 (1%)	0.667
Antihypertensive drugs	7813 (46.8%)	1921 (46%)	1956 (46.9%)	1943 (46.5%)	1993 (47.7%)	0.45

Data are n (%), mean (SD), and median (IQR).

The significance of differences in population characteristics between groups was computed using signed-rank tests, or χ^2 tests, for continuous and categorical variables.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; HDL-C, high-density lipoprotein cholesterol; *MTHFR*, methylenetetrahydrofolate reductase; SBP, systolic blood pressure.

Table 2 Cross-sectional and longitudinal association between baseline vitamin B₁₂ levels and diabetes (DM) and new-onset DM

Baseline vitamin B ₁₂	Cross-sectional*				Longitudinal†			
	DM		New-onset DM		DM		New-onset DM	
	n	Cases (%)	Non-adjusted OR (95% CI), p value	Adjusted OR (95% CI), p value	n	Cases (%)	Non-adjusted OR (95% CI), p value	Adjusted OR (95% CI), p value
Continuous (per IQR)	16 699	1872 (11.2)	1.36 (1.28 to 1.44), <0.001	1.35 (1.26 to 1.44), <0.001	14 827	1589 (10.7)	1.02 (0.95 to 1.09), 0.572	0.97 (0.90 to 1.04), 0.346
Quartiles								
Q1	4175	353 (8.5)	1	1	3707	391 (10.5)	1	1
Q2	4173	404 (9.7)	1.15 (0.99 to 1.34), 0.071	1.02 (0.87 to 1.21), 0.788	3706	383 (10.3)	0.99 (0.85 to 1.14), 0.849	0.94 (0.80 to 1.10), 0.447
Q3	4176	493 (11.8)	1.47 (1.27 to 1.69), <0.001	1.23 (1.04 to 1.44), 0.013	3707	417 (11.2)	1.07 (0.92 to 1.24), 0.387	0.98 (0.83 to 1.14), 0.768
Q4	4175	622 (14.9)	1.83 (1.59 to 2.11), <0.001	1.68 (1.43 to 1.98), <0.001	3707	398 (10.7)	1.02 (0.88 to 1.18), 0.820	0.91 (0.77 to 1.07), 0.244
P for trend			<0.001	<0.001			0.582	0.341

*Adjusted for age, sex, *MTHFR* gene C677T polymorphisms, SBP and DBP at baseline, body mass index, study center, serum concentrations of folate, homocysteine, total cholesterol, triglycerides, and high-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, smoking status, alcohol consumption status, meat consumption, lipid-lowering drugs and antihypertensive drugs.

†Adjusted for age, sex, *MTHFR* gene C677T polymorphisms, SBP and DBP at baseline, mean SBP and DBP during the treatment period, body mass index, study center, baseline serum concentrations of folate, homocysteine, fasting blood glucose, total cholesterol, triglycerides, and high-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, treatment group, smoking status, alcohol consumption status, meat consumption, lipid-lowering drugs and antihypertensive drugs.

DBP, diastolic blood pressure; DM, diabetes mellitus; *MTHFR*, methylenetetrahydrofolate reductase; SBP, systolic blood pressure.

Table 3 Cross-sectional and longitudinal association between baseline vitamin B₁₂ and baseline FBG, exit FBG and change in FBG (Δ FBG)

Baseline vitamin B ₁₂	Cross-sectional*				Longitudinal†				Δ FBG			
	Baseline FBG		Exit FBG		Baseline FBG		Exit FBG		Baseline FBG		Exit FBG	
	Mean (SD)	Non-adjusted β (95% CI), p value	Adjusted β (95% CI), p value	Adjusted β (95% CI), p value	Mean (SD)	Non-adjusted β (95% CI), p value	Adjusted β (95% CI), p value	Adjusted β (95% CI), p value	Mean (SD)	Non-adjusted β (95% CI), p value	Adjusted β (95% CI), p value	Adjusted β (95% CI), p value
Continuous (per IQR)	5.8 (1.7)	0.16 (0.13 to 0.19), <0.001	0.14 (0.11 to 0.17), <0.001	0.13 (0.09 to 0.17), <0.001	6.3 (2.0)	0.13 (0.09 to 0.17), <0.001	-0.01 (-0.04 to 0.02), 0.602	-0.02 (-0.05 to 0.01), 0.163	0.5 (1.6)	-0.02 (-0.05 to 0.01), 0.163	-0.01 (-0.04 to 0.02), 0.602	-0.01 (-0.04 to 0.02), 0.602
Quartiles												
Q1	5.6 (1.3)	0	0	0	6.1 (1.7)	0	0	0	0.5 (1.5)	0	0	0
Q2	5.8 (1.5)	0.11 (0.04 to 0.18), 0.002	0.03 (-0.04 to 0.09), 0.381	0.07 (-0.01 to 0.16), 0.094	6.2 (2.0)	0.07 (-0.01 to 0.16), 0.094	-0.01 (-0.08 to 0.05), 0.736	-0.04 (-0.11 to 0.03), 0.241	0.5 (1.7)	-0.04 (-0.11 to 0.03), 0.241	-0.01 (-0.08 to 0.05), 0.696	-0.01 (-0.08 to 0.05), 0.696
Q3	5.9 (1.7)	0.23 (0.16 to 0.31), <0.001	0.13 (0.06 to 0.19), <0.001	0.19 (0.10 to 0.28), <0.001	6.3 (2.1)	0.19 (0.10 to 0.28), <0.001	0.00 (-0.06 to 0.07), 0.935	-0.05 (-0.12 to 0.02), 0.144	0.5 (1.7)	-0.05 (-0.12 to 0.02), 0.144	-0.00 (-0.07 to 0.06), 0.979	-0.00 (-0.07 to 0.06), 0.979
Q4	5.9 (2.1)	0.31 (0.24 to 0.38), <0.001	0.26 (0.20 to 0.33), <0.001	0.23 (0.14 to 0.32), <0.001	6.4 (2.2)	0.23 (0.14 to 0.32), <0.001	-0.03 (-0.10 to 0.03), 0.325	-0.05 (-0.12 to 0.02), 0.168	0.4 (1.7)	-0.05 (-0.12 to 0.02), 0.168	-0.03 (-0.10 to 0.03), 0.316	-0.03 (-0.10 to 0.03), 0.316
P for trend		<0.001	<0.001	<0.001		<0.001	0.462	0.162		0.162	0.405	0.405

*Adjusted for age, sex, MTHFR gene C677T polymorphisms, SBP and DBP at baseline, body mass index, study center, serum concentrations of folate, homocysteine, total cholesterol, triglycerides, and high-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, smoking status, alcohol consumption status, meat consumption, lipid-lowering drugs and antihypertensive drugs.

†Adjusted for age, sex, MTHFR gene C677T polymorphisms, SBP and DBP at baseline, mean SBP and DBP during the treatment period, body mass index, study center, baseline serum concentrations of folate, homocysteine, FBG, total cholesterol, triglycerides, and high-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, treatment group, smoking status, alcohol consumption status, meat consumption, lipid-lowering drugs and antihypertensive drugs.

DBP, diastolic blood pressure; FBG, fasting blood glucose; MTHFR, methyltetrahydrofolate reductase; SBP, systolic blood pressure.

change in vitamin B₁₂ and change in FBG levels (table 4, figure 1).

DISCUSSION

This is the first time that the relationship between vitamin B₁₂ and DM has been explored in a Chinese population of patients with hypertension via both cross-sectional and longitudinal analyses. We confirmed the findings of the NHANES, showing a cross-sectional positive association between vitamin B₁₂ and DM at baseline in this Chinese population. Furthermore, our longitudinal analyses demonstrated that there was no association between baseline vitamin B₁₂ levels and new-onset DM risk. Our study has contributed new insights on the vitamin B₁₂ and DM association and has helped to explain inconsistent findings in previous studies.

Vitamin B₁₂ and DM association depends on population characteristics

Most previous studies on the association of vitamin B₁₂ and DM were centered on vitamin B₁₂ deficiency among existing patients with DM with the use of metformin. The association between metformin use and low vitamin B₁₂ levels has been supported by various levels of evidence.⁴ Most of those studies were conducted in older populations, where vitamin B₁₂ deficiency is more likely.⁸ In contrast, our study was conducted in a Chinese population of patients with hypertension who were relatively young (45–75 years at baseline), mostly free from DM at baseline, and mostly vitamin B₁₂ sufficient. Only 6.9% of the study participants with DM reported using metformin (online supplementary figure S4).

Vitamin B₁₂ and DM association depends on the study design and type of analyses

In a Mendelian randomization study, Moen *et al*¹⁴ found that vitamin B₁₂ may have a causal effect on fasting glucose and one potential mechanism could be an effect of vitamin B₁₂ on cell cycle and proliferation of pancreatic β cells, resulting in improved insulin secretion among individuals with higher vitamin B₁₂ concentrations. However, in other cross-sectional analyses, Jayashri *et al*⁶ found that the levels of vitamin B₁₂ decreased with increasing severity of glucose tolerance. Margalit *et al*¹⁵ found no significant difference in blood sugar between the vitamin B₁₂-deficient group and the non-deficient group. In longitudinal analyses and randomized trials, Looker *et al*¹⁶ found that vitamin B₁₂ was positively associated with all-cause mortality and death from diabetes/nephropathy. Song *et al*⁷ found that daily supplementation with folic acid and vitamins B₆ and B₁₂ did not reduce the risk of developing type 2 diabetes among women at high risk for cardiovascular diseases (CVD). Kwok *et al*¹⁷ found that vitamin B₁₂ supplementation did not prevent cognitive decline in older patients with diabetes with borderline vitamin B₁₂ status. In a systematic review, Rafnsson *et al*¹⁸ found that current data do not support vitamin B₁₂

Table 4 Longitudinal analyses on change in vitamin B₁₂ (ΔB_{12}) and change in FBG (ΔFBG) from baseline to exit visit*

Exposure	n	Mean (SD)	ΔFBG ($\mu\text{mol/L}$)			
			Non-adjusted model		Adjusted model†	
$\Delta \text{Vitamin B}_{12}$			β (95% CI)	P value	β (95% CI)	P value
Continuous (per IQR)	4366	-15.4 (299.5)	0.02 (0.00 to 0.04)	0.018	0.01 (0.00 to 0.02)	0.144
Quartiles						
Q1	1092	-149.1 (155.3)	0		0	
Q2	1091	-38.4 (13.5)	0.05 (-0.09 to 0.19)	0.479	-0.02 (-0.14 to 0.11)	0.789
Q3	1091	6.5 (13.5)	0.23 (0.09 to 0.37)	0.001	0.11 (-0.01 to 0.24)	0.082
Q4	1092	119.2 (545.2)	0.34 (0.20 to 0.48)	<0.001	0.20 (0.08 to 0.33)	0.002
P for trend				<0.001		<0.001

*This subsample included a total of 4366 subjects with both baseline and exit FBG and vitamin B₁₂ measurements.

†Adjusted for age, sex, *MTHFR* gene C677T polymorphisms, SBP and DBP at baseline, mean SBP and DBP during the treatment period, body mass index, study center, baseline serum concentrations of folate, homocysteine, FBG, B₁₂, total cholesterol, triglycerides, and high-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, treatment group, smoking status, alcohol consumption status, meat consumption, lipid-lowering drugs and antihypertensive drugs.

DBP, diastolic blood pressure; FBG, fasting blood glucose; *MTHFR*, methylenetetrahydrofolate reductase; SBP, systolic blood pressure.

supplementation in reducing the risk of cardiovascular diseases or diabetes.

Our study was the first to perform and report findings from both cross-sectional and longitudinal analyses in the same population. In the cross-sectional analysis, we found an independent, positive association between baseline vitamin B₁₂ levels and DM and FBG. These results persisted even after we adjusted for relevant covariables. This finding is consistent with the NHANES study.⁸ In the longitudinal analyses, we did not find any association between baseline vitamin B₁₂ and new-onset DM risk. This finding is consistent with the Women's

Antioxidant and Folic Acid Cardiovascular Study, where women aged ≥ 40 years with a history of cardiovascular disease, who were free of DM at baseline, were supplemented with either a combination pill consisting of folic acid, pyridoxine and vitamin B₁₂, or a placebo. After a median follow-up of 7.3 years, no difference in incident type 2 diabetes mellitus was found between the two groups.⁷ Another longitudinal study¹⁹ in Japan also reported similar null results. Taken together, our longitudinal analyses and that of others did not support an association between vitamin B₁₂ and new-onset DM. These findings underscore that cross-sectional associations need to be confirmed by prospective studies and clinical trials, because the former is more likely to be subject to many drawbacks, including reverse causality.

Clinical implications of findings

The role of vitamin B₁₂ in DM varied by patient characteristics. Most previous studies have shown that vitamin B₁₂ supplementation is necessary in elderly patients with diabetes with low vitamin B₁₂ levels or in patients with diabetes with long-term metformin use.^{8 17 20} Our study, along with other longitudinal studies, however, does not support the routine use of vitamin B₁₂ supplementation to reduce the risk of new-onset DM¹⁸ in relatively young patients with no evidence of vitamin B₁₂ deficiency. Moreover, a meta-analysis by Valdés-Ramos *et al*²¹ indicated no recommendation for the use of vitamin supplements in patients with type 2 diabetes mellitus. Of note, the research of Looker *et al*¹⁶ showed that vitamin B₁₂ was positively associated with all-cause mortality and death from diabetes/nephropathy, and previous data also indicated that elevated serum vitamin B₁₂ levels are a predictive factor for mortality in elderly patients with cancer.²² Salles *et al*²³ and Hemmersbach-Miller *et al*²⁴ reported that higher vitamin B₁₂ levels might also be a marker to assess a higher risk of mortality in elderly patients. Vitamin B₁₂

Figure 1 Multivariable-adjusted smoothing curves of change in vitamin B₁₂ and change in FBG in a subsample that included a total of 4366 subjects with both baseline and exit FBG and vitamin B₁₂ measurements. Adjusted for age, sex, *MTHFR* gene C677T polymorphisms, SBP and DBP at baseline, mean SBP and DBP during the treatment period, body mass index, study center, baseline serum concentrations of folate, homocysteine, FBG, vitamin B₁₂, total cholesterol, triglycerides, and high-density lipoprotein cholesterol, treatment group, smoking status, and alcohol consumption status. DBP, diastolic blood pressure; FBG, fasting blood glucose; *MTHFR*, methylenetetrahydrofolate reductase; SBP, systolic blood pressure.

can also accelerate decline in renal function and increase the risk of cardiovascular events in patients with impaired renal function.^{25 26} Zeitlin *et al*²⁷ also suggest that for elderly people, vitamin B₁₂ supplementation should not be routinely provided unless there are clear indications for doing so (a deficiency state), and then to only replace enough vitamin B₁₂ to correct the deficiency. Through our research and analysis, we found that vitamin B₁₂ may still have a correlation with blood glucose or DM, and the disappearance of this correlation in the longitudinal analysis may be due to the relative changes in the observation age, the decrease in vitamin B₁₂ levels and the increase in FBG levels over time. Therefore, the relationship between the changes in indicators needs to be observed to reflect real results. We found that the change in vitamin B₁₂ levels and the change in FBG levels showed a positive vitamin B₁₂–FBG association in the subsample. In addition, we repeated the previous analysis with this subsample and found the results were consistent with those of the previous analysis (online supplementary table S3).

The present study had some limitations. First, this study focused on Chinese adults with hypertension, so the generalizability of the results to other populations remains to be determined. Second, new-onset DM was not a primary outcome or a prespecified outcome of the CSPPT. We did not obtain FBG measurements at the scheduled follow-up visits, nor did we measure hemoglobin A1c or perform glucose tolerance tests at baseline or during the follow-up visits. Therefore, it is possible that we have underestimated the incidence of new-onset DM in the CSPPT. Nevertheless, we believe that any potential underestimation of new-onset DM should be non-differential, and therefore should not significantly affect the results. Finally, we only measured vitamin B₁₂ levels on a small subset (n=4366) of the population at the exit visit and were unable to examine vitamin B₁₂ dynamics during the follow-up period of the CSPPT.

CONCLUSION

Among a population of adults with hypertension in China without a history of stroke or MI, who were mostly vitamin B₁₂-sufficient, there was a dose–response association of vitamin B₁₂ levels with the risk of DM based on cross-sectional analyses at baseline. There was no prospective relationship between baseline vitamin B₁₂ and new-onset DM in the longitudinal analyses. However, in a subsample, a positive vitamin B₁₂–FBG association was shown by the change in vitamin B₁₂ levels and the change in FBG levels. This result indicates that there may be a potential correlation between B₁₂ and diabetes. Our findings illustrate a clear discrepancy in results from the cross-sectional and longitudinal analyses even from the same study population, and underscore the need to consider both baseline and longitudinal changes between vitamin B₁₂ and FBG in order to better elucidate the role of vitamin B₁₂ in the

development of diabetes. If further studies confirm such findings, this will have an important impact on clinical and public health.

Author affiliations

¹Beijing Advanced Innovation Center for Food Nutrition and Human Health, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, China

²Department of Cardiology, Nanchang University Second Affiliated Hospital, Nanchang, Jiangxi, China

³National Clinical Research Study Center for Kidney Disease, the State Key Laboratory for Organ Failure Research, Renal Division, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China

⁴Institute of Biomedicine, Anhui Medical University, Hefei, Anhui, China

⁵Shenzhen Evergreen Medical Institute, Shenzhen, China

⁶College of Pharmacy, Jinan University, Guangzhou, Guangdong, China

⁷School of Public Health (Shenzhen), Sun Yat-Sen University, Guangzhou, Guangdong, China

⁸Guangdong Engineering Technology Center of Nutrition Transformation, Guangzhou, China

⁹Department of Nutrition, School of Public Health, Sun Yat-Sen University, Guangzhou, China

¹⁰Department of Cardiology, Peking University First Hospital, Beijing, China

¹¹School of Medicine, Lebanese American University, Beirut, Lebanon

¹²Department of Population, Family and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA

Contributors XX, YH and HZ critically revised the protocol for research design. LL, XH, YS, TL, ZZ, ZW, PC, and GT were responsible for implementation on-site. LL, XH and CL performed the statistical analyses. LL and XH drafted the manuscript. XW, PAZ, YY, WL, JL, YZ, YL, XQ and BW developed the methodological approach. All authors contributed to the conception and design and approved the final version of the manuscript.

Funding The China Stroke Primary Prevention Trial (CSPPT) was jointly supported by Shenzhen AUSA Pharmed (Shenzhen, China) and national, provincial and private funding, including from the Major State Basic Research Development Program of China (973 Program; grant no. 2102 CB517703); the National Science and Technology Major Projects Specialized for 'Innovation and Development of Major New Drugs' during the 12th Five-year Plan Period: the China Stroke Primary Prevention Trial (grant no. zx09101105); a Clinical Center grant (no. zx09401013); the Projects of the National Natural Science Foundation of China (grant no. 81473052, 81441091, and 81402735); the National Clinical Research Center for Kidney Disease, Nanfang Hospital, Nanfang Medical University, Guangzhou, China; the State Key Laboratory for Organ Failure Research, Nanfang Hospital; and research grants from the Department of Development and Reform, Shenzhen Municipal Government (grant no. SFG 20201744).

Disclaimer The funding organizations and/or sponsor participated in the study design, but had no role in the conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.

Competing interests XX reports grants from the National Key Research and Development Program (2016YFE0205400, 2018ZX09739010, 2018ZX09301034003), the Science and Technology Planning Project of Guangzhou, China (201707020010), the Science, Technology and Innovation Committee of Shenzhen (JSGG20170412155639040, GJHS20170314114526143, JSGG20180703155802047), and the Economic, Trade and Information Commission of Shenzhen Municipality (20170505161556110, 20170505160926390). YL reports grants from the President Foundation of Nanfang Hospital, Southern Medical University (2017C007, 2018Z009). XQ reports grants from the National Natural Science Foundation of China (81730019, 81973133) and Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University (2017J009). HG reports grants from the 111 Project from the Education Ministry of China (B18053). XH reports grants from the National Natural Science Foundation of China (81960074, 81500233), Jiangxi Outstanding Person Foundation (20192BCBL23024), and major projects of the Science and Technology Department, Jiangxi (20171BAB205008).

Patient consent for publication Not required.

Ethics approval The parent study (the CSPPT) was approved by the Ethics Committee of the Institute of Biomedicine, Anhui Medical University, Hefei, China (Federal-wide Assurance Number: FWA00001263).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Hao Zhang <http://orcid.org/0000-0003-4148-1739>

REFERENCES

- Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. *Lancet* 2017;389:2239–51.
- Chinese Diabetes Society, National Office for Primary Diabetes Care. [National guidelines for the prevention and control of diabetes in primary care(2018)]. *Zhonghua Nei Ke Za Zhi* 2018;57:885–93.
- O'Leary F, Samman S. Vitamin B12 in health and disease. *Nutrients* 2010;2:299–316.
- Yang W, Cai X, Wu H, et al. Associations between metformin use and vitamin B₁₂ levels, anemia, and neuropathy in patients with diabetes: a meta-analysis. *J Diabetes* 2019;11:729–43.
- Bauman WA, Shaw S, Jayatilake E, et al. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. *Diabetes Care* 2000;23:1227–31.
- Jayashri R, Venkatesan U, Rohan M, et al. Prevalence of vitamin B₁₂ deficiency in South Indians with different grades of glucose tolerance. *Acta Diabetol* 2018;55:1283–93.
- Song Y, Cook NR, Albert CM, et al. Effect of homocysteine-lowering treatment with folic acid and B vitamins on risk of type 2 diabetes in women: a randomized, controlled trial. *Diabetes* 2009;58:1921–8.
- Reinstatler L, Qi YP, Williamson RS, et al. Association of biochemical B₁₂ deficiency with metformin therapy and vitamin B₁₂ supplements: the National health and nutrition examination survey, 1999–2006. *Diabetes Care* 2012;35:327–33.
- Huo Y, Li J, Qin X, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. *JAMA* 2015;313:1325–35.
- Huang X, Li Y, Li P, et al. Association between percent decline in serum total homocysteine and risk of first stroke. *Neurology* 2017;89:2101–7.
- Huang X, Qin X, Yang W, et al. MTHFR Gene and Serum Folate Interaction on Serum Homocysteine Lowering: Prospect for Precision Folic Acid Treatment. *Arterioscler Thromb Vasc Biol* 2018;38:679–85.
- American Diabetes Association. 2. Classification and Diagnosis of Diabetes: *Standards of Medical Care in Diabetes-2018*. *Diabetes Care* 2018;41:S13–27.
- Hunt A, Harrington D, Robinson S. Vitamin B12 deficiency. *BMJ* 2014;349:g5226.
- Moen G-H, Qvigstad E, Birkeland KI, et al. Are serum concentrations of vitamin B-12 causally related to cardiometabolic risk factors and disease? A Mendelian randomization study. *Am J Clin Nutr* 2018;108:398–404.
- Margalit I, Cohen E, Goldberg E, et al. Vitamin B12 deficiency and the role of gender: a cross-sectional study of a large cohort. *Ann Nutr Metab* 2018;72:265–71.
- Looker HC, Fagot-Campagna A, Gunter EW, et al. Homocysteine and vitamin B(12) concentrations and mortality rates in type 2 diabetes. *Diabetes Metab Res Rev* 2007;23:193–201.
- Kwok T, Lee J, Ma RC, et al. A randomized placebo controlled trial of vitamin B₁₂ supplementation to prevent cognitive decline in older diabetic people with borderline low serum vitamin B₁₂. *Clin Nutr* 2017;36:1509–15.
- Rafnsson SB, Saravanan P, Bhopal RS, et al. Is a low blood level of vitamin B12 a cardiovascular and diabetes risk factor? A systematic review of cohort studies. *Eur J Nutr* 2011;50:97–106.
- Eshak ES, Iso H, Muraki I, et al. Among the water-soluble vitamins, dietary intakes of vitamins C, B₂ and folate are associated with the reduced risk of diabetes in Japanese women but not men. *Br J Nutr* 2019;121:1357–64.
- Gupta K, Jain A, Rohatgi A. An observational study of vitamin B12 levels and peripheral neuropathy profile in patients of diabetes mellitus on metformin therapy. *Diabetes Metab Syndr* 2018;12:51–8.
- Valdés-Ramos R, Guadarrama-López AL, Martínez-Carrillo BE, et al. Vitamins and type 2 diabetes mellitus. *Endocr Metab Immune Disord Drug Targets* 2015;15:54–63.
- Geissbühler P, Mermillod B, Rapin CH. Elevated serum vitamin B12 levels associated with CRP as a predictive factor of mortality in palliative care cancer patients: a prospective study over five years. *J Pain Symptom Manage* 2000;20:93–103.
- Salles N, Herrmann F, Sakbani K, et al. High vitamin B12 level: a strong predictor of mortality in elderly inpatients. *J Am Geriatr Soc* 2005;53:917–8.
- Hemmersbach-Miller M, Conde-Martel A, Betancor-León P. Vitamin B as a predictor of mortality in elderly patients. *J Am Geriatr Soc* 2005;53:2035–6.
- Spence JD, Yi Q, Hankey GJ. B vitamins in stroke prevention: time to reconsider. *Lancet Neurol* 2017;16:750–60.
- House AA, Eliasziw M, Catran DC, et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. *JAMA* 2010;303:1603–9.
- Zeitlin A, Frishman WH, Chang CJ. The association of vitamin B 12 and folate blood levels with mortality and cardiovascular morbidity incidence in the old old: the Bronx aging study. *Am J Ther* 1997;4:275–81.